BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36418170)

  • 1. Phase III Study of
    Olivier P; Giraudet AL; Skanjeti A; Merlin C; Weinmann P; Rudolph I; Hoepping A; Gauthé M
    J Nucl Med; 2023 Apr; 64(4):579-585. PubMed ID: 36418170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of
    Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN
    Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Ferrari C; Mammucci P; Lavelli V; Pisani AR; Nappi AG; Rubini D; Sardaro A; Rubini G
    Tomography; 2022 Nov; 8(6):2709-2722. PubMed ID: 36412685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P
    Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Performance and Clinical Impact of
    Cerci JJ; Fanti S; Lobato EE; Kunikowska J; Alonso O; Medina S; Novruzov F; Lengana T; Granados C; Kumar R; Rangarajan V; Al-Ibraheem A; Hourani M; Ali NS; Ahmad A; Keidar Z; Küçük O; Elboga U; Bogoni M; Paez D
    J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of
    Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study.
    Panagiotidis E; Fragkiadaki V; Papathanasiou N; Kypraios C; Liatsikos E; Klampatsas A; Paschali A; Exarhos D; Zarokosta F; Chatzipavlidou V; Apostolopoulos D; Datseris I
    Nucl Med Commun; 2023 Dec; 44(12):1126-1134. PubMed ID: 37779440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results of a
    Rousseau C; Le Thiec M; Ferrer L; Rusu D; Rauscher A; Maucherat B; Frindel M; Baumgartner P; Fleury V; Denis A; Morel A; Varmenot N; Debeaupuis E; Campion L; Kraeber-Bodéré F
    Prostate; 2019 Sep; 79(13):1514-1522. PubMed ID: 31421657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Impact of
    Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
    Witkowska-Patena E; Giżewska A; Dziuk M; Miśko J; Budzyńska A; Walęcka-Mazur A
    Clin Nucl Med; 2019 Dec; 44(12):e629-e633. PubMed ID: 31689286
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
    Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparison of whole-body MRI and
    Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.
    Lengana T; Lawal I; Janse Van Rensburg C; Mokoala K; Moshokoa E; Mazibuko S; Van de Wiele C; Maes A; Vorster M; Sathekge MM
    Nuklearmedizin; 2022 Apr; 61(2):120-129. PubMed ID: 35421900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of
    De Man K; Piron S; Van Laeken N; Delrue L; Fonteyne V; Lumen N; Van den Broeck B; Kersemans K; Ost P; Schelfhout V
    Mol Imaging Biol; 2022 Oct; 24(5):750-758. PubMed ID: 35411446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
    Morawitz J; Kirchner J; Lakes J; Bruckmann NM; Mamlins E; Hiester A; Aissa J; Loberg C; Schimmöller L; Arsov C; Antke C; Albers P; Antoch G; Sawicki LM
    Eur J Radiol; 2021 Mar; 136():109556. PubMed ID: 33485127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.